Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04691986 · ClinicalTrials.gov registry record · NA
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans
A NA study of Sarcopenia and Nicotinamide Adenine Dinucleotide Concentration, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT04691986 is a NA study of Sarcopenia and Nicotinamide Adenine Dinucleotide Concentration that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 144 participants, above the 77-participant average among 41 other Sarcopenia trials with a reported enrollment target (87% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04691986, a NA study of Sarcopenia and Nicotinamide Adenine Dinucleotide Concentration, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Nicotinamide Riboside
Study Locations (1)
Missouri
- Kansas City VA Medical Center, Kansas City, MO - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04691986
The ClinicalTrials.gov registry entry for NCT04691986 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 77-participant average among 41 other Sarcopenia trials with a reported enrollment target (87% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sarcopenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04691986 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT04691986 about?
NCT04691986 is a clinical study titled "Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans". Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been l...
What is the current status of trial NCT04691986?
This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2023-09-01. Estimated completion is 2026-06-30.
What conditions does trial NCT04691986 study?
This clinical trial studies the following conditions: Sarcopenia, Nicotinamide Adenine Dinucleotide Concentration, Muscle Quality and NAD+ Content.
What interventions are being tested in trial NCT04691986?
The interventions under investigation include: Placebo (OTHER), Nicotinamide Riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04691986?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04691986 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Spinal Motoneuronal Activation in Older Adults
RECRUITING · NA
-
Strength Training and Resveratrol
RECRUITING · NA
-
Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment
RECRUITING · NA
-
Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
RECRUITING · NA
-
C-Protein in Fatigue and Aging
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.